SHILPAMED · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 59/100 — Quality 68 · Valuation 21 · Momentum 100
| Share price | ₹625.45 |
| Market cap | ₹12,266 Cr |
| P/E ratio | 50.0 |
| P/B ratio | 4.7 |
| ROCE | 14.5% |
| Dividend yield | 0.08% |
| Book value | ₹132.46 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹1,539 Cr | ₹243 Cr | 28.0% |
| 2025 | ₹1,281 Cr | ₹78 Cr | 25.0% |
| 2024 | ₹1,146 Cr | ₹32 Cr | 21.0% |
| 2023 | ₹1,046 Cr | ₹-31 Cr | 9.0% |
| 2022 | ₹1,141 Cr | ₹61 Cr | 18.0% |
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine,